Ido Yofe

🚀 YOFE LAB LAUNCHES 🚀 As a #newPI at Sheba Medical Center I'm building a cutting-edge research lab, addressing a critical challenge – how to stop #Cancer #Metastasis before it spreads. Looking for research assistants and students to join us! Apply here: Join.Yofe.Lab@gmail.com

In patients with stage II/III HER2-positive or triple-negative breast cancer receiving neoadjuvant therapy (NAT): ctDNA tells the real story: * Post-NAT ctDNA+ → HR 8.9 (recurrence risk) * Post-op ctDNA+ → HR 128 (!! recurrence risk) * ctDNA− → 5y IDFS 94% Not a response marker. A recurrence biology marker. pCR is a snapshot. ctDNA is the future. 👉 We now need trials testing escalation strategies in ctDNA-positive patients — and whether converting ctDNA to negative improves outcomes. @OncoAlert @myESMO @ASCOPost @PTarantinoMD @Dr_Oncologista #breastcancer ascopubs.org/doi/10.1200/JC…

Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!🤯 ⁦thanks to ⁦@nyscf⁩ ⁦@parkerici⁩ for their support. Today at ⁦@Nature⁩ nature.com/articles/s4158…

Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.

This

ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. nature.com/articles/s4159…

"We envision a future where MRD is not only detected but also targeted in a personalized manner, with the ultimate goal of eradicating it to improve survival rates" 🎯

New research in @CCR_AACR shows the powerful clinical utility of detecting minimal residual disease in ovarian cancer patients. Co-first author and Gynecologic Oncology fellow at @MDAndersonNews, and co-first author on this study, @AnneKniselyMD shares her thoughts Learn more here: breakthroughcancer.org/2025/08/new-st… Read the full study here: aacrjournals.org/clincancerres/…

@OdedRechavi @TyHaliburton22 Well that jinxed it

Every night it gets crazier and crazier... can't imagine what might happen tomorrow... but my money is on @TyHaliburton22

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

@leeat_keren Looks awesome, looking forward to trying it!

🚨Preprint Alert!🚨 Cell classification is one of the most difficult tasks in analyzing spatial data. We present CellTune - a powerful toolkit for accelerating biological discovery in spatial proteomics. 📄 biorxiv.org/content/10.110… 👇🧵1/7

Fantastic study! Great work @FadiSheban @TgSanPhan @CuriousKX @FlorianIngelfi1

@leeat_keren Nice! Congratulations everyone! @RazBenuri @LiorBenSha @omerbartal @OneViTaDay @OferElhanani

Super excited to finally see this published! Our new method to use combinatorial staining and deep learning to push the multiplexing boundaries of spatial proteomics!

We are beyond excited to share the first publication of our lab! We highlight the role of #neutrophils in shaping a more aggressive #TME through physical interactions with #breastcancer cells. The work was led by the talented @Sandra_Cam & @OriMoskowitz 🧵nature.com/articles/s4301…

@RoychoudhuriLab @JieYang437 @Nature @Cambridge_Uni @CRUKCamCentre Remarkable 👏 Congratulations to all authors, inspiring work.

Thrilled to share new work led by @JieYang437 in the lab published today in @Nature. We find that Aspirin prevents metastasis by releasing T cells from immune suppression by platelet TXA2. @Cambridge_Uni @CRUKCamCentre rdcu.be/eci1U

Highly recommended

The Yofe Lab at Sheba is looking for scientists: 🥼Research Associate • PhD & MSc students 🎓 Our new cancer research group is focused on studying metastasis with cutting-edge tech. Interested? Send your CV & cover letter to: Join.Yofe.Lab@gmail.com

Proud to be part of @SHEBA_, a world-leading hospital. sheba-global.com/sheba-ranks-8-…

גאווה ישראלית: שיבא מטפס למקום ה-8 בעולם! המרכז הרפואי שיבא ממשיך להוביל ומטפס למקום ה-8 בדירוג בתי החולים הטובים בעולם של Newsweek – הישג בינלאומי יוצא דופן למערכת הבריאות הישראלית. השנה האחרונה הציבה אתגר עצום, ושיבא היה בלב המענה הרפואי:

Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary brnw.ch/21wQWsx By corresponding author and #AACRIO25 speaker Ido Amit @IdoAmitLab

7/Uncover the immune landscape of metastatic niches. This study maps single-cell profiles, identifying TREM2+ regulatory macrophages at invasive margins as drivers of immune evasion. @IdoYofe @IdoAmitLab pubmed.ncbi.nlm.nih.gov/37756565/